[ad_1]
The brand of Novo Nordisk is displayed on the eighth China Worldwide Import Expo.
Sheldon Cooper | Lightrocket | Getty Photos
Novo Nordisk mentioned on Tuesday its experimental weight problems drug, amycretin, confirmed statistically important weight lack of as much as 14.5% at 36 weeks in sufferers with kind 2 diabetes in a mid-stage research.
The drugmaker’s Denmark-listed shares have been up 2.5%.
Amycretin, the corporate’s next-generation weight problems drug, has a dual-mode motion, focusing on the intestine hormone GLP-1 and a pancreatic hormone known as amylin.
The research examined once-weekly subcutaneous and oral amycretin in comparison with placebo in 448 individuals with kind 2 diabetes inadequately managed on metformin with or with out an SGLT2 inhibitor, a standard class of diabetes remedy, Novo mentioned.
The info validates the potential best-in-class profile of amycretin, mentioned Martin Holst Lange, chief scientific officer and government vice chairman of analysis and growth at Novo Nordisk.
The corporate mentioned the drug appeared secure and effectively tolerated, with largely mild-to-moderate gastrointestinal unwanted side effects. It plans to begin late-stage trials in 2026.
Amycretin is one in every of Novo’s next-generation experimental medicine which may enable it to increase its earnings past its 2031-2032 semaglutide patent expiries, HSBC analysts had mentioned in a word earlier this yr.
Weekly injections of amycretin had helped chubby sufferers lose 22% of their weight in 36 weeks, in line with early-stage trial outcomes revealed in January.
Final yr, the tablet model helped sufferers lose as much as 13.1% of their weight after 12 weeks in an early-stage trial.
[ad_2]
